Shulan Medical submitted a Main Board listing application to the Hong Kong Stock Exchange on March 27. CICC and CITIC Securities are its co-sponsors. The company's revenue was 1,547.8 billion yuan in 2021, 1,777.6 billion yuan in 2022, and 1,884.4 billion yuan in 2023. In 2021, 2022 and 2023, adjusted net profit was $21.2 million, $6.3 million and $82.8 million, respectively, measured according to non-IFRS.
树兰医疗向港交所提交上市申请
Shulan Medical submits listing application to the Hong Kong Stock Exchange
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.